Ending a temporary federal stabilisation programme after 2026 hands rising drug costs back to plans and patients and could push millions of stand-alone Part D enrollees into Medicare Advantage. The demonstration had trimmed the national base beneficiary premium by £15 equivalent in 2025 and the equivalent of £10 in 2026 and capped year-on-year premium rises at $35 in 2025 and $50 in 2026. Those measures lowered the average stand-alone Part D premium by $26 in 2025 and $16 in 2026. CMS says most beneficiaries will see premiums rise by less than $10 in 2027, but advocates warn some enrollees will face noticeably higher bills as drug costs climb. The change affects roughly 24.9 million people in stand-alone Part D plans in 2026, up from 22.8 million in 2024, and could accelerate a move into Medicare Advantage.
The decision reads like a market correction, but it removes subsidies that cost taxpayers nearly $10 billion over two years. The Government Accountability Office and subsequent policy analyses put the combined federal cost of the demonstration at $9.8 billion for 2025 and 2026. CMS framed ending the programme as rolling back what it described as an unnecessary bailout. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, wrote that the prior administration "gave BILLIONS of taxpayer money DIRECTLY to Big Insurance Companies."
The Stabilization Demonstration had two mechanics. First, it lowered the national base beneficiary premium, which is the benchmark used to calculate individual plan charges, by $15 in 2025 and $10 in 2026. Second, it imposed caps on how much insurers could raise premiums year on year, $35 in 2025 and $50 in 2026. Those measures reduced the average stand-alone Part D premium by $26 in 2025 and by $16 in 2026, figures cited by MedPAC and KFF.
Those headline reductions concealed a persistent trend. Even with the subsidies, the average monthly premium for a stand-alone Part D plan was about $36 in 2026, more than four times the roughly $8 average drug component embedded in Medicare Advantage plans, MedPAC and KFF report.
That gap matters because Medicare Advantage sponsors can use rebates to buy down premiums for MA-PD products, a mechanism unavailable to beneficiaries in traditional Medicare who rely on stand-alone PDPs.
Policy changes under the Inflation Reduction Act are the original shock. The IRA moved catastrophic drug costs onto plan sponsors and introduced out-of-pocket caps of $2,000 in 2025 and $2,100 in 2026. When insurers signalled sharp premium increases in 2024, CMS announced the stabilization programme to blunt abrupt spikes and keep enrolment stable. It worked in that narrow sense: the demonstration limited immediate premium volatility and likely reduced churn among stand-alone plans. It did not, however, halt the longer term pressures from rising drug prices and greater use of high-cost medicines such as GLP-1s and specialty therapies.
That arithmetic will now play out at plan level. Analysts and consumer advocates warn that some stand-alone Part D enrollees will face materially higher bills in 2027 because the demonstration had insulated plans from IRA-driven cost pressures. Insurers who absorbed less of those costs while the subsidies ran may respond to their underlying exposures with bigger increases when they submit 2027 bids. The Trump administration cited examples of large insurer payments under the demonstration, and analysts flagged that some companies benefited more than others, so the final picture will be uneven across plans and regions.
CMS has tried to temper alarm, saying most enrollees will see modest changes. The agency has scheduled an official release of plan premium details in September and urged beneficiaries to review plan-level disclosures. Consumers who depend on stand-alone PDP coverage will be able to compare options during Medicare open enrollment, which runs from October 15 through December 7 for coverage beginning January 1, 2027.
There is a simple policy inference. First, the market structure advantage enjoyed by Medicare Advantage, through rebate-driven premium design, makes MA an attractive option for beneficiaries seeking lower drug premiums. Second, the termination of a costly federal stabiliser hands the immediate bill back to plans and enrollees, so the short-term premium signal will reveal how insurers choose to allocate rising pharmacy costs between premiums, benefits and cost-sharing.
Related Articles
CMS will publish detailed premium and plan information in September, and beneficiaries can use Medicare open enrollment from October 15 to December 7 to change coverage for January 1, 2027. Originally reported by kff.org.
This article was created with AI assistance.
